| X | Filing Date | Trade Date | Ticker | Insider Name | Title | Trade Type | Price | Qty | Owned | ΔOwn | Value | 1d | 1w | 1m | 6m | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-15 | KROS | Pontifax Management 4 G.P. (2015) Ltd. | 10% | S - Sale | $17.75 | -4,787,331 | 10,500 | -100% | -$84,975,125 | ||||||
| 2025-10-15 | KROS | Adar1 Capital Management, LLC | 10% | S - Sale | $17.75 | -5,389,264 | 0 | -100% | -$95,659,436 | ||||||
| D | 2025-04-09 | KROS | Adar1 Capital Management, LLC | 10% | P - Purchase | $10.13 | +934,258 | 5,390,964 | +21% | +$9,464,512 | |||||
| A | 2024-01-04 | KROS | Regnante Keith | CFO | S - Sale | $45.29 | -40,000 | 0 | -100% | -$1,811,600 | |||||
| 2024-08-13 | KROS | Gordon Carl L | Dir | S - Sale | $44.01 | -250,000 | 119,522 | -68% | -$11,002,500 | ||||||
| 2024-08-13 | KROS | Orbimed Advisors LLC | Dir | S - Sale | $44.01 | -250,000 | 119,522 | -68% | -$11,002,500 | ||||||
| D | 2023-11-04 | KROS | Regnante Keith | CFO | S - Sale+OE | $45.29 | -40,000 | 0 | -100% | -$1,811,600 | 
| A | Amended filing | 
| D | Derivative transaction in filing (usually option exercise) | 
| E | Error detected in filing | 
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price | 
| S - Sale | Sale of securities on an exchange or to another person | 
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) | 
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company | 
| P - Purchase | Purchase of securities on an exchange or from another person |